Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Touts Expanded Product Lineup as it Wraps up ParAllele Acquisition

NEW YORK, Oct. 24 (GenomeWeb News) - As GenomeWeb News reported earlier today, Affymetrix confirmed today that it has closed the acquisition of privately held ParAllele BioScience in a stock-and-cash transaction worth around $121 million.

 

Affymetrix said in a statement that ParAllele stockholders approved the acquisition on Oct. 20, and that it was completed on Oct. 21.

 

ParAllele stockholders will receive around $120.8 million in the form of $11.7 million in cash and around 2.29 million shares of Affymetrix common stock.

 

Stephen Fodor, founder and CEO of Affymetrix, said in a conference call following the company's third-quarter earnings last Thursday that he expects "a quick and successful integration of companies" in the wake of the acquisition.

 

Affymetrix "will launch a series of innovative new products, including a product covering 20K coding DNA SNPs, several disease-specific SNP panels including inflammation and cancer, and an expanding range of custom SNP panels spanning 1,500 to 20,000 SNPs," Fodor said.

 

Affymetrix said in a statement that it will add 1,500 new SNP custom assays and 20,000 non-synonymous coding SNP assays to its product portfolio as a result of the acquisition.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.